This study looks at how well a new medicine called rocatinlimab works to help people with moderate-to-severe asthma. Asthma is a disease that makes it hard to breathe. This study is for people aged 18 to 75 who have had asthma for at least a year and are already taking certain medicines for it.

To join the study, participants must have used inhaled corticosteroids (ICS) like fluticasone and at least one other asthma controller medicine for at least 90 days before the study. They should have had at least one asthma flare-up in the past year. People who have a history of severe asthma attacks leading to the emergency room or hospital visits are not eligible.

Key Points:

• The study includes several doctor visits, but details on exact number are not provided.
• Participants will receive the study medication, rocatinlimab, but any compensation for participation isn't mentioned.
• Potential risks may include side effects from the medication, but specific risks aren't listed.